TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium
…is people likely unfamiliar with the melanoma world and melanoma research—because at the time of the biopsy, they won’t even…
TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium
…is people likely unfamiliar with the melanoma world and melanoma research—because at the time of the biopsy, they won’t even…
,
Summary of Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
…of progression to unresectable (meaning it cannot be removed by surgery) melanoma before surgery, disease recurrence (meaning the return of…
,
In Plain English: What’s New in Stage II?
…second layer). It is mainly differentiated from Stage I melanoma by having a thicker Breslow depth. Stage II melanoma is…
,
President’s Update June | 2020
…up-to-date information for melanoma patients, caregivers, and families. Over the years, many people with nonmelanoma skin cancer—specifically squamous cell skin…
,
SCERF: What it is and Why You Need to Know About it
…unlike all other cancers, non-melanoma skin cancer is not required to be documented and counted in a cancer registry. These…
THE GRATITUDE GALA: AIM’s 3rd Annual No Show Gala & Online Auction
…impact on people living with melanoma—but there’s real hope for the future too. As a melanoma research and advocacy foundation,…
,
The Tutu Brothers: Using Skirts and Sneakers to Fight Melanoma
…want to save the world, but in this case, the bad guy is melanoma. Since they met in 2012 at…
,
,
The Future of Melanoma Treatment: 2023 and Beyond
…treatment of melanoma and other cutaneous malignancies, particularly in the application of sentinel lymph node biopsy and lymph node dissection…
,
Remembering Brandon Blackstock: A Call to Action on Melanoma Awareness
Difficult News and A Reminder of the Impact of Melanoma Today we would like to acknowledge the recent death of…
,
Announcement of the Passing of Val Guild, Founder & President of AIM
…lost her 26-year-old daughter to melanoma and founded what would become AIM at Melanoma, Val became a force—a guiding light—in…
Recent Posts
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026